Teva Pharmaceutical Industries Limited (TEVA) Balance Sheet

The balance sheet is deleveraging gradually, with total debt down from $19.9B in 2024Q1 to $16.9B in 2026Q2, while equity has fluctuated but shows a slight upward trend from $5.4B in 2024Q4 to $7.8B in 2026Q2. This suggests a deliberate focus on debt reduction, consistent with prior cash flow findings of no capital returns. However, the equity base is still thin relative to the debt load, leaving limited cushion against adverse developments.

Although debt has decreased by roughly $3B from its peak, the absolute level is still substantial, and the D/E ratio, while improved, remains above 2.0. This leverage appears strategic for a company with significant legal liabilities and a need to fund operations, but it also implies that a portion of cash flow must be dedicated to servicing debt. Investors should monitor refinancing risk, especially if interest rates remain high, as the company's ability to generate consistent free cash flow has been uneven.

The asset mix is heavily weighted toward goodwill, which has remained stable around $15.5-16.5B over the past ten quarters, suggesting no major impairments yet. However, this concentration raises the risk of future write-downs if the generics business underperforms. The relatively low PPE suggests a manufacturing model that is not capital-intensive, but the high goodwill means that the balance sheet's quality is dependent on the sustained profitability of acquired businesses.

Equity is constrained by a large retained deficit, which has improved modestly as the company has generated some profits, but the deficit remains substantial. This indicates that past losses have eroded the equity base, and while recent profitability has helped, the company is still rebuilding. The lack of dividends and buybacks, as noted in cash flow analysis, supports the notion that earnings are being retained to repair the balance sheet, but the pace is slow.

The current ratio has been below 1.0 in several quarters, indicating that current liabilities exceed current assets, which could strain short-term obligations. Cash has increased from $2.2B in 2025Q3 to $3.7B in 2026Q2, providing some buffer, but the overall liquidity remains modest relative to the debt load. This suggests that Teva may rely on refinancing or asset sales to meet near-term obligations, and any operational hiccup could exacerbate liquidity pressures.